Pacific Edge (PEB)

Business description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

Rights offer to support expansion

Update | Pharmaceutical & healthcare | 17/08/2015

Pacific Edge raised NZ$35.3m in a rights issue, which completed in early July. Funds are to be used mainly to provide cash for continued commercialisation of its Cxbladder diagnostics tests in its primary US market, as well as to fuel international expansion. The company also recently announced its first User Programme in South-East Asia with the completion of an agreement with Singaporean hospital Tan Tock Seng representing the start of its stated intent to capture the significant South- East Asian market. Pacific Edge also reported full-year results at the end of May, largely in line with our expectations.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.NZ$177.2m
Last closeNZ$0.380
High / Low (52 weeks)NZ$0.6 / NZ$0.3
Stock market listingNZ
Forecast net cash (NZ$m)22.8
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(8.8)6.6(41.2)

* % Relative to local index

Company news

Pacific Edge

Tue, 13 Mar 2018 21:22:30 GMT

Pacific Edge

Sun, 21 Jan 2018 22:52:30 GMT

Pacific Edge

Mon, 16 May 2016 20:01:58 GMT

Pacific Edge

Tue, 26 May 2015 13:03:54 GMT

Pacific Edge

Wed, 13 Dec 2017 22:35:06 GMT